Novartis India Past Earnings Performance
Past criteria checks 5/6
Novartis India has been growing earnings at an average annual rate of 22.7%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 6.5% per year. Novartis India's return on equity is 13.6%, and it has net margins of 28.9%.
Key information
22.7%
Earnings growth rate
22.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -6.5% |
| Return on equity | 13.6% |
| Net Margin | 28.9% |
| Next Earnings Update | 10 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Novartis India makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3,300 | 955 | 302 | 0 |
| 30 Sep 23 | 3,257 | 766 | 329 | 0 |
| 30 Jun 23 | 3,484 | 712 | 392 | 0 |
| 31 Mar 23 | 3,787 | 1,034 | 423 | 0 |
| 31 Dec 22 | 4,009 | 550 | 581 | 0 |
| 30 Sep 22 | 4,197 | 537 | 751 | 0 |
| 30 Jun 22 | 4,227 | 424 | 907 | 0 |
| 31 Mar 22 | 3,999 | -37 | 1,094 | 0 |
| 31 Dec 21 | 4,008 | 294 | 1,155 | 0 |
| 30 Sep 21 | 3,957 | 223 | 1,189 | 0 |
| 30 Jun 21 | 3,870 | 228 | 1,169 | 0 |
| 31 Mar 21 | 3,814 | 209 | 1,187 | 0 |
| 31 Dec 20 | 3,758 | 180 | 1,248 | 0 |
| 30 Sep 20 | 3,995 | 264 | 1,260 | 0 |
| 30 Jun 20 | 4,214 | 137 | 1,279 | 0 |
| 31 Mar 20 | 4,383 | 101 | 1,282 | 0 |
| 31 Dec 19 | 4,549 | 228 | 1,393 | 0 |
| 30 Sep 19 | 4,731 | 280 | 1,357 | 0 |
| 30 Jun 19 | 4,619 | 426 | 1,397 | 0 |
| 31 Mar 19 | 4,907 | 518 | 1,480 | 0 |
| 31 Dec 18 | 5,056 | 587 | 1,726 | 0 |
| 30 Sep 18 | 5,261 | 646 | 1,846 | 0 |
| 30 Jun 18 | 5,872 | 813 | 1,890 | 0 |
| 31 Mar 18 | 5,639 | 784 | 1,836 | 0 |
| 31 Dec 17 | 5,840 | 548 | 1,850 | 0 |
| 30 Sep 17 | 5,923 | 491 | 1,832 | 0 |
| 30 Jun 17 | 5,997 | 452 | 1,725 | 0 |
| 31 Mar 17 | 6,562 | 572 | 1,814 | 0 |
| 31 Dec 16 | 6,455 | 836 | 1,138 | 0 |
| 30 Sep 16 | 6,734 | 1,290 | 1,222 | 0 |
| 30 Jun 16 | 7,223 | 2,104 | 1,382 | 0 |
| 31 Mar 16 | 6,930 | 725 | 2,006 | 0 |
| 31 Dec 15 | 7,305 | 926 | 1,668 | 0 |
| 30 Sep 15 | 7,601 | 836 | 1,805 | 0 |
| 30 Jun 15 | 7,705 | 785 | 1,782 | 0 |
| 31 Mar 15 | 7,552 | 793 | 1,671 | 0 |
| 31 Dec 14 | 8,638 | 558 | 4,418 | 0 |
| 30 Sep 14 | 8,693 | 675 | 4,256 | 0 |
| 30 Jun 14 | 8,507 | 990 | 4,191 | 0 |
| 31 Mar 14 | 7,276 | 857 | 1,465 | 0 |
| 31 Dec 13 | 8,720 | 991 | 3,924 | 0 |
| 30 Sep 13 | 8,819 | 1,128 | 3,940 | 0 |
| 30 Jun 13 | 9,071 | 1,066 | 3,895 | 0 |
Quality Earnings: 500672 has high quality earnings.
Growing Profit Margin: 500672's current net profit margins (28.9%) are higher than last year (13.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 500672's earnings have grown significantly by 22.7% per year over the past 5 years.
Accelerating Growth: 500672's earnings growth over the past year (73.8%) exceeds its 5-year average (22.7% per year).
Earnings vs Industry: 500672 earnings growth over the past year (73.8%) exceeded the Pharmaceuticals industry 23.1%.
Return on Equity
High ROE: 500672's Return on Equity (13.6%) is considered low.